BioCentury | Apr 30, 2020
Distillery Therapeutics

Heparan sulfate for prevention of acetaminophen-induced acute liver failure

...GMP synthesis, safety testing and clinical development. Asahi Kasei Pharma Corp. markets the HMGB1 inhibitor Recomodulin...
BioCentury | Jul 24, 2014
Distillery Therapeutics

Indication: Hepatic disease

...understand the roles of specific HMGB1 isoforms in liver disease. Asahi Kasei Pharma Corp. markets Recomodulin...
BioCentury | Feb 27, 2014
Targets & Mechanisms

The XII factor

...GCC4401C (small molecule) Phase I VTE; stroke Thrombin (factor IIa; F2) Asahi Kasei Pharma Corp. Recomodulin...
BioCentury | Nov 12, 2012
Clinical News

Recomodulin: Phase III started

...Asahi Kasei began a double-blind, placebo-controlled, international Phase III trial to evaluate 0.06 mg/kg IV ART-123...
...as Recomodulin to treat disseminated intravascular coagulation. Asahi Kasei Pharma Corp. , Tokyo, Japan Product: Recomodulin...
...to treat disseminated intravascular coagulation. Asahi Kasei Pharma Corp. , Tokyo, Japan Product: Recomodulin ( ART-123...
BioCentury | Nov 21, 2011
Company News

Artisan Pharma, Asahi Kasei Pharma deal

...Artisan will become its base for U.S. development of pharmaceuticals. Artisan has rights to Asahi's ART-123...
...IIb trial to treat disseminated intravascular coagulation (DIC) in sepsis. The product is marketed as Recomodulin...
BioCentury | May 3, 2010
Clinical News

ART-123: Completed Phase IIb enrollment

...750 sepsis patients in a double-blind, placebo-controlled, international Phase IIb trial evaluating 6 mg/mL injectable ART-123...
...for the indication in Japan. Artisan spun out of Asahi in 2006, getting rights to ART-123...
...2006). Artisan Pharma Inc. , Waltham, Mass. Asahi Kasei Pharma Corp. , Tokyo, Japan Product: ART-123...
BioCentury | Feb 26, 2009
Distillery Therapeutics

Indication: Transplantation

...TLR4 signal transduction inhibitor from Takeda Pharmaceutical Co. Ltd., is in Phase III for sepsis. ART-123...
BioCentury | Feb 5, 2009
Distillery Therapeutics

Indication: Infectious disease

...Neuprex opebacan targeting lipopolysaccharide in Phase II and Phase I/II testing, respectively, to treat sepsis. ART-123...
BioCentury | Sep 29, 2008
Emerging Company Profile

Artisan: Testing, testing 123

...2006 to develop and commercialize ART-123 outside of Asia to treat disseminated intravascular coagulation (DIC). ART-123...
...patient's thrombin levels, because the ART-123-thrombin complex is required in order to activate protein C. "ART-123...
...patients given ART-123 vs. 49.9% of heparin-treated patients. Resolution of DIC was the primary endpoint. ART-123...
BioCentury | Sep 29, 2008
Emerging Company Profile

Corporate Profile

...Artisan Pharma Inc. Waltham, Mass. Technology: Recombinant human thrombomodulin ( ART-123 ) Disease focus: Cardiovascular Clinical...
...NovaQuest CEO: Jeffrey Wager Patents: One issued in the U.S. covering composition of matter of ART-123 BC...
Items per page:
1 - 10 of 18